RxDoctor Payments DataLook up a doctor →

John Puente, MD

Neurology · Fremont, NENPI 1194775916

Payments from drug & device makers

$1,316,742in general payments, 2019–2025

Across 2,255 payments — averaging $583.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$384K
  • AbbVie$255K
  • Sage Therapeutics, LLC$242K
  • Lexicon Pharmaceuticals, Inc.$106K
  • Biogen$81K
  • Acadia Pharmaceuticals Inc$52K
  • plus $196K from 54 others

What the payments were for

  • Consulting fees$32,07218%
  • Speaking & faculty fees$105,68259%
  • Travel & lodging$9,3725%
  • Food & beverage$31,78618%
  • Education$3480%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis199$383,858
AbbVie(2 entities)228$255,426
Sage Therapeutics, LLC19$241,609
Lexicon Pharmaceuticals, Inc.27$106,182
Biogen239$80,998
Acadia Pharmaceuticals Inc50$52,124
Sanofi75$45,743
Amgen(2 entities)60$31,534
Otsuka Pharmaceutical Development & Commercialization, Inc.3$24,035
EMD Serono, Inc.68$21,065
Genentech USA, Inc.68$16,492
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$14,500
Bristol Myers Squibb103$13,272
E.r. Squibb & Sons, L.L.C.11$6,134
Adamas Pharmaceuticals, Inc.38$4,949
Livanova USA, Inc.21$2,441
Pfizer31$2,027
MDD US Operations, LLC24$1,906
Lilly USA, LLC81$1,242
Teva Pharmaceuticals USA, Inc.80$1,033
Eisai Inc.36$742
Lundbeck LLC43$726
Supernus Pharmaceuticals, Inc.219$649
Biohaven Pharmaceuticals, Inc.53$630
Johnson & Johnson(2 entities)43$607
Neurocrine Biosciences, Inc.52$581
UCB, Inc.52$513
Amneal Pharmaceuticals LLC36$457
Jazz Pharmaceuticals Inc.22$426
TG Therapeutics, Inc.13$397
Sunovion Pharmaceuticals Inc.35$372
Biohaven Pharmaceutical Holding Company Ltd.29$326
AstraZeneca(2 entities)14$269
GRT US Holding, Inc.6$261
SK Life Science, Inc.10$204
Mallinckrodt Hospital Products Inc.8$199
Arbor Pharmaceuticals, Inc.10$172
Neurelis, Inc.9$168
Avanir Pharmaceuticals, Inc.10$168
Genentech, Inc.4$165
Greenwich Biosciences, Inc.10$159
Upsher-smith Laboratories LLC7$153
Impel Pharmaceuticals Inc.11$150
Tanabe Pharma America, Inc.8$128
Otsuka America Pharmaceutical, Inc.4$118
ANI Pharmaceuticals, Inc.6$114
Kyowa Kirin, Inc.5$103
Acorda Therapeutics, Inc5$79
Medtronic4$78
Sumitomo Pharma America, Inc.8$78
Vanda Pharmaceuticals Inc.3$70
Catalyst Pharmaceuticals, Inc.4$68
Merck4$67
Axsome Therapeutics, Inc.4$63
Argenx US, Inc.4$62
Sanofi-aventis U.S. LLC2$58
Boston Scientific3$47
Ipsen Biopharmaceuticals, Inc3$45
Hospira, Inc.3$39
Averitas Pharma Inc.2$38

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,316,742 in reported general payments places this provider in the 95th percentile of 105 neurology providers in Nebraska.

See all neurology providers in Nebraska

Medicare billing

Part B allowed, 2024
$148,888
Medicare patients
522
Services billed
12,447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab26$240,837
NuplazidPimavanserin Tartrate44$163,611
IngrezzaValbenazine Tosylate19$162,616
Aimovig AutoinjectorErenumab-Aooe137$108,274
FycompaPerampanel50$62,424
QuliptaAtogepant51$61,617
BriviactBrivaracetam38$60,615
GocovriAmantadine Hcl23$54,686
Nurtec OdtRimegepant Sulfate42$52,393
Glatiramer Acetate12$50,192
Emgality PenGalcanezumab-Gnlm52$37,001
UbrelvyUbrogepant33$35,866
Emgality SyringeGalcanezumab-Gnlm13$20,097
Ajovy AutoinjectorFremanezumab-Vfrm24$18,699
VimpatLacosamide11$13,804

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$52,124$163,61144 claims
Neurocrine Biosciences, Inc.Ingrezza$581$162,61619 claims
AbbVieQulipta, Ubrelvy$255,426$97,48384 claims
UCB, Inc.Briviact, Vimpat$513$74,41849 claims
Eisai Inc.Fycompa$742$62,42450 claims
MDD US Operations, LLCGocovri$1,906$54,68623 claims
PfizerNurtec Odt$2,027$52,39342 claims
Amneal Pharmaceuticals LLCRytary$457$7,28323 claims
Upsher-smith Laboratories LLCTopiramate$153$1,725199 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 105 neurology providers in Nebraska.

Other neurology in Fremont

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →